Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today provided an update on its activities and cash position as of March 31, 2017.

With the PDUFA dates now set for both VyzultaTM and ZERVIATE, we are focussing our resources on the partnering activities for ZERVIATE in the United States and on preparing for the initiation of the Phase 2 studies evaluating our promising pipeline candidates NCX 4251 in the fourth quarter of 2017 and NCX 470 in the first quarter of 2018,” said Michele Garufi, Chairman and Chief Executive Officer of Nicox.Subject to approval by the FDA, we expect to have two revenue-generating assets and have two candidates in the clinic within the next 12 months, which would put us in a strong position as a major R&D player with an extensive clinical and preclinical pipeline in the ophthalmic space.”

First-quarter 2017 financial highlights

The Group had cash, cash equivalents and financial instruments of €25.0 million3 as of March 31, 2017, compared to €28.9 million as of December 31, 2016. The Group recorded no revenues for the first quarter 2017.

First-quarter 2017 and recent operational highlights

Key upcoming milestones

Notes:
1. VyzultaTM is the provisionally approved tradename for latanoprostene bunod ophthalmic solution, 0.024%
2. ZERVIATE is the tradename provisionally approved for cetirizine ophthalmic solution, 0.24%
3. Figures non audited